



Contemporary outcomes of debridement, antibiotics and implant retention (DAIR) in hip arthroplasty

Marie-Ève Bolduc¹, Daniel Fischman², Ben Kendrick³, Adrian Taylor³, George Grammatopoulos²

¹CHUM - Centre Hospitalier de l'Université de Montréal, Montreal, Québec, Canada; ²Division of Orthopedic Surgery, The Ottawa Hospital, Ottawa, Ontario, Canada; ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

Contributions: (I) Conception and design: All authors; (II) Administrative support: All authors; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: George Grammatopoulos, MBBS, BSc, FRCS (Tr. & Ortho), DPhil (Oxon). Division of Orthopaedic Surgery, The Ottawa Hospital – General Campus, 501 Smyth Road, CCW 1638, Ottawa, ON, K1H 8L6, Canada. Email: ggrammatopoulos@toh.ca.

Abstract: A debridement, antibiotic-treatment and implant-retention (DAIR) is a valuable surgical option in the treatment of hip periprosthetic joint infection (PJI). Although the indications for DAIR remain controversial, it should be considered in all hip PJI cases with a soundly fixed prosthesis, despite chronicity and type of implant. DAIR is associated with significant reduced cost and better patient reported outcomes compared to 2-stage revision. Variable success, defined as eradication of infection, has been reported following DAIR (14% to 100%) which is partly due to heterogeneity of the cohorts reported, the length of follow-up and the various definitions of success used. The success following DAIR has continuously improved since 2004, with a pooled mean chance of success of 72.2%. A number of variables have been associated with chances of success that need to be considered, when surgeons decide to proceed with a DAIR. Those can be broadly divided into patient-, PJI-, surgical- and antibiotic-related factors; all of which are covered in this review. It is our opinion that a DAIR can achieve PJI eradication in the majority of patients in the hands of experienced surgeons in specialised centres with a multi-disciplinary team approach. Exchange of modular components and thorough debridement are paramount.

Keywords: Hip; periprosthetic joint infection (PJI); antibiotic-treatment and implant-retention (DAIR); outcome

Received: 19 May 2020; Accepted: 24 July 2020; Published: 15 October 2021.

doi: 10.21037/aoj-20-87

View this article at: <http://dx.doi.org/10.21037/aoj-20-87>

Introduction

The incidence of hip periprosthetic joint infection (PJI) is thought to be 0.5% to 2% (1). As a result, PJI is one of the leading causes of revision following hip arthroplasty. Given the projected increase in hip arthroplasty volume, the burden of PJI is likely to increase in the future. PJI is a devastating complication following THA, for the patient, the surgeon, the healthcare system and the society overall. It is associated with reduced patient outcome [as measured by morbidity-, mortality-rates (2) and quality of life measures (3)] and increased cost (4). It is also an incommensurable

psychosocial stressor for the patients, as the fear of disease progression is comparable to that seen in oncology patients (5).

Although indications for a debridement, antibiotic-treatment and implant-retention (DAIR), remain controversial, it is a surgical procedure that one ought to consider in the treatment of PJI. In this review article we aim to (I) provide the reader with a brief, contemporary, description of a DAIR; (II) define outcomes described in the literature; and (III) describe factors associated with improved chances of success.

What is a DAIR?

History

Coventry was amongst the first to describe what a DAIR procedure entails “radical debridement of all necrotic debris”; when it should not be considered, “when the components were loose, or bone involvement was present”; and what the post-operative regimen should entail, “patients were treated with irrigation with an appropriate antibiotic and were maintained on high doses of parenteral antibiotics for as long as possible” (6).

Description of technique

During a DAIR, the surgical team, would excise all infected (or potentially infected) tissue along all tissue planes, i.e., from the skin down to the prosthesis. Thus, the procedure would typically involve a radical debridement of involved skin, excision of any sinus tracts present, inflammatory tissues present superficial and deep to the fascia lata, a debridement of the capsule and the synovium along with any inflammatory tissue around the prostheses. Copious irrigation and exchange of modular components are strongly advised (7). A DAIR is not a simple arthrotomy or incision and drainage or washout. Although a DAIR is considered, the least invasive surgical option, it may be associated with significant blood loss due to the extensive dissection (‘to healthy bleeding tissue’) that is necessary for adequate debridement. Post-operative hemoglobin levels are similar to those seen after revision arthroplasty and half of patients require blood transfusion (8). In addition, it is our opinion that it is best performed by an arthroplasty surgeon who would be more comfortable to perform the radical excision in order to achieve the necessary debridement. It is crucial to assess the integrity of the interfaces (bone implant and bone-cement when present) as a compromised interface will reduce chances of success.

Although surgery is an important part of the DAIR, so is the medical aspect of treatment. Patient optimization pre- and post-procedure, along with appropriate antibiotic guidance lead by infection disease physicians is paramount. Broad spectrum antibiotic therapy should be used whilst culture results are pending. Once the pathogen is known, treatment regimen and duration should be agreed upon by the surgical and medical teams. Total duration of antibiotic therapy varies greatly in the literature, from six weeks to six months, but treatment should always be tailored to the

patient (9,10). There is some evidence that treatment for longer than three months only delays failure rather than decreases the risk of failure (11).

The use of bio-absorbable antibiotic carriers (e.g., calcium sulphate or resorbable sponges) is becoming increasingly popular to deliver high doses of antibiotics locally, but no high-level evidence is at present available regarding the efficacy of such adjuvants in the literature.

Multi-disciplinary aspect

It is key that these patients are treated by a multidisciplinary team. Ideally, this would include specialist nurses, therapists (physiotherapists, occupational therapists), infectious disease physicians, and plastic surgeons in addition to the orthopedic team.

DAIR in hip arthroplasty

DAIR should be considered in all hip PJI cases, despite chronicity, with well-fixed implant and sound interfaces (implant-bone or implant-cement/cement-bone) (12).

DAIR in primary total hip arthroplasty

Success rates following DAIR have been quite varied (14% to 100%), which is partly due to heterogeneity of the cohorts reported, the length of follow-up and the various definitions of success (13-21) (*Table 1*).

The most comprehensive definition of PJI eradication is at present the modified Delphi criteria, described in the recent International Consensus (10). However, whether this is fully applicable for a DAIR can be a matter of debate as in several series, authors have advocated more than one debridement procedure as part of the ‘DAIR approach’. Thus, a repeat procedure would be considered as failure of treatment as per the modified Delphi criteria. It is our opinion, that in cases of desired PJI eradication a second DAIR procedure is only moderately likely to be a success and hence, strong consideration should be given to revision arthroplasty if the patient can tolerate the procedure.

The studies reporting on outcomes after DAIR are predominantly of small cohorts, and most of them are of retrospective design. In a systematic review of 39 case-control and cohort studies from 1971 to 2016 that included 1,296 patients, Tsang *et al.* reported that the success following DAIR has continuously improved since 2004. The

Table 1 Previous studies (1998–onwards) reporting on outcome following DAIR

Study	Joint	No of cases [hips]	Follow-up/years, mean [range]	Success %	Exchanged modular parts	Most common organism	Complication rate	Predictors of poor outcome
Crockarell et al. 1998	Hip	42	6 [0–22]	26	No	CoNS (11%)	12%	n/a
Tattevin et al. 1999	Hip/knee	34	2 [0–6]	38	No	<i>S. Aureus</i> (74%)	n/a	Symptoms >5 days
Krasin et al. 2001	Hip	7	2.5	29	No	Gram+	n/a	n/a
Meehan et al. 2003	Hip/knee	19 [6]	4 [0–22]	90	26%	Group G Strep	n/a	n/a
Soriano et al. 2003	Hip	10	2	90	No	Mixed	n/a	n/a
Berdal et al. 2005	Hip/knee	29 [20]	2	83	Yes	<i>S. Aureus</i> (62%)	n/a	n/a
Marculescu et al. 2006	Hip/knee	99 [47]	2 [1–8]	60	48%	<i>S. Aureus</i> (32%)	n/a	Sinus tract, symptoms >5 days
Theis et al. 2004	Hip	36	4.5	53	No	Gram+	n/a	n/a
Aboltins et al. 2007	Hip/knee	20 [13]	2 [1–6]	88	Yes	MRSA (50%)	n/a	n/a
Martinez-Paster et al. 2009	Hip/knee	47 [15]	1 [1–3]	75	Yes	<i>Enterobacteria</i> (87%) ^x	n/a	CRP
Parvisi et al. 2009	Hip	24	Min 2	33	No	Gram+	n/a	n/a
Byren et al. 2009	Hip/knee	112 [52]	n/a	81	n/a	<i>S. Aureus</i> (42%)	n/a	Revisions, arthroscopic washout, <i>S. aureus</i>
Tintle et al. 2009	Hip	3	3	100	Yes	Mixed	n/a	n/a
Aboltins et al. 2011	Hip/knee	17 [15]	2 [0–8]	88	Yes	<i>E. Coli</i> (30%) ^x	n/a	n/a
Azzam et al. 2010	Hip/knee	106 [53]	6 [2–10]	66	29%	<i>Staphylococcal</i> (46%)	n/a	<i>Staphylococcus</i> , high ASA, Frank pus
Van Kleunen et al. 2010	Hip/knee	18 [13]	3 [1–5]	72	72%	MSSA (50%)	n/a	Surgery after 4 weeks from implantation
Estes et al. 2010	Hip/knee	20 [4]	4 [1–8]	90	Yes	MSSA (20%)	n/a	n/a
Cobo et al. 2010	Hip/knee	117 [69]	2 [0–3]	57	Yes	<i>S. Aureus</i> (40%)	n/a	Centre 'C' (1 of 9 centres in study)
Klouche et al. 2011	Hip	12	3 [2–4]	75	18%	<i>Streptococci</i> (58%)	n/a	n/a
Koyonos et al. 2011	Hip/knee	138 [60]	5 [1–10]	35	No	<i>Staphylococcal</i>	n/a	<i>Staphylococcus</i> , chronic infection
Choi et al. 2012	Hip	28	5 [1–10]	68	68%	<i>S. Aureus</i> (25%)	n/a	Revision, polymicrobial, <i>S. aureus</i>
Sukeik et al. 2012	Hip	26	7 [5–11]	77	Yes	<i>S. Aureus</i> (31%)	n/a	Symptoms >5 days
Buller et al. 2012	Hip/knee	309 [62]	3 [0–13]	52	Partly	CoNS (20%)	n/a	Symptoms >21 days, <i>Staphylococcus</i>

Table 1 (continued)

Table 1 (continued)

Study	Joint	No of cases [hips]	Follow-up/years, mean [range]	Success %	Exchanged modular parts	Most common organism	Complication rate	Predictors of poor outcome
Geurts <i>et al.</i> 2013	Hip	69	2	83	No	Gram+	n/a	Delay of treatment ≥ 8 weeks
Peel <i>et al.</i> 2013	Hip	28	2.5	71	Yes	Gram+	n/a	n/a
Westberg <i>et al.</i> 2013	Hip	38	4 [1–10]	71	Yes	<i>S. Aureus</i> (26%)	42%	Polymicrobial infection
Kuiper <i>et al.</i> 2013	Hip/knee	91 [62]	3 [0–6]	66	Most	<i>S. Aureus</i>	n/a	CoNS, late infection, symptoms > 7 days
Konigsberg <i>et al.</i> 2014	Hip	42 [20]	4.5	80	Yes	Gram+	n/a	<i>Staphylococcus</i>
Betz <i>et al.</i> 2014	Hip	38	3.5	82	Yes	Gram+	n/a	<i>Staphylococcus aureus</i>
Moojen <i>et al.</i> 2014	Hip	33	4	88	Yes	Gram+	n/a	n/a
Triantafyllopoulos <i>et al.</i> 2015	Hip	60	5 [1–14]	70	Yes	MSSA (30%)	n/a	Symptoms > 5 days, BMI, MRSA
Tornero <i>et al.</i> 2015	Hip/knee	222 [87]	0.2	77	73%	CoNS	n/a	Kidney/liver failure, revision, CRP, cemented
Chaussade <i>et al.</i> 2017	Hip/knee	87 [60]	4	69	Yes	Mixed	n/a	<i>Staph. aureus</i>
Grammatopoulos <i>et al.</i> 2017	Hip	82	8	85	55%	Mixed	43%	Symptoms > 7 days, no exchange of modular components, loose components
Barros <i>et al.</i> 2019	Hip/knee	38 [12]	3.5	89.50	Yes	Mixed	n/a	Late treatment, no exchange of components

Success defined as infection eradication. ^x study involving Gram-ve organisms only. Strep, Streptococcus; MRSA, methicillin resistant *Staphylococcus aureus*; MSSA, methicillin sensitive *Staphylococcus aureus*; CoNS: coagulase negative *Staphylococcus*; DAIR, antibiotic-treatment and implant-retention.

overall chance of success was 72.2% (21). As the authors pointed out, this may be due to a learning effect following the paper by Zimmerli that better defined treatment algorithms and management in PJI (22). Improved success was noted when DAIRs were performed early (<7 days; 75.7%) and when the modular components were exchanged as part of the procedure (77.5%).

We have previously reported a PJI-center's institutional experience with 122 THA DAIRs (7,12). Overall, eradication was seen in 68% with the initial DAIR. In 32 cases, additional DAIR(s) was required. Infection eradication was seen in 85% of cases (104/122) when single or multiple DAIRs were performed. Of the twenty-one hips that underwent revision (17%), the majority (n=16) were for persistent PJI. In this cohort, the 10-year implant survivorship was 77%. Factors independently associated with a 4-fold increased PJI eradication and improved implant survivorship with DAIR were (1) early PJI and (2) exchange of modular components. We also reported a study comparing 3 case-matched groups; primary THAs, DAIRs and two stage revisions and the last of one with primary elective THA (12). The complication rate was similar between the two PJI groups (DAIR: 38%, 2-stage revision: 29%; P=0.2). Similar PJI eradication was seen between both groups also (DAIR: 85% vs. 2-stage revision: 89%; P=0.5). Kaplan Meier analysis illustrated similar implant survivorship at 10 years between the DAIR and 2-stage revision groups. When DAIR was successful in eradicating PJI, implant survivorship in those hips with PJI eradication (98%) was akin to that seen with primary THA (98%).

DAIR in revision arthroplasty

Outcome of DAIR is inferior in the revision THA. In the series reported by Tornero *et al.*, revision surgery was an independent predictor of lack of PJI eradication (i.e., failure), with a greater failure rate of 12–22% compared to that seen in primary arthroplasty (23). A DAIR is a suitable option for all different types of revision implants, including megaprotheses. Although surgical options remain the same to other arthroplasties, the morbidity associated with revision procedures is greater and thus a DAIR is an attractive option. Treatment algorithm must be made on an individual basis and account for a number of parameters including concomitant medical conditions, surgical history, PJI history, organism identified, and patient wishes. However, data on outcome in this challenging patient group is limited and of small series (24,25).

Functional outcome following DAIR

Advocates of DAIR would argue that a procedure not disturbing a well fixed prosthesis and any associated interfaces) is likely to be associated with superior outcomes compared with revision surgery (26,27).

We have previously reported on patient reported outcome using the Oxford Hip Score (OHS) post DAIR for a number of patients. Superior OHS was seen in patients who had a DAIR following primary THA (OHS: 39) compared to those having a DAIR following revision surgery (OHS: 26). Better OHS was seen when no complications were sustained post-DAIR (OHS: 39); however outcome was inferior when complications were encountered (OHS: 25).

In order to better determine how functional outcome following DAIR compares to that of an uncomplicated primary total hip arthroplasty and a two-stage revision, a case-control study was performed. Patients that had a DAIR had inferior OHS [38] compared to primary THAs [42] but the OHS was significantly better compared with patients that underwent two-stage revision [31]. Two further studies have since reported similar findings (26,28). Patient reported outcome following DAIR (HOOS and HHS/QOL) was like that seen in primary THA, especially if there were no complications related to the DAIR procedures.

Mortality following DAIR

Most studies reporting on mortality rates in PJI don't distinguish between types of treatment, being either DAIR, single-stage or two-stage revision.

A population-based cohort study from the Danish registry, linking to other National databases reported an 8% 1-year mortality rate in patients who underwent revision for PJI; which was significantly greater compared to 5% for the group revised for reasons other than PJI and 2% for the group who had no undergone a revision (29).

We have also previously reported high mortality rate in a hip DAIR cohort of 13% at 5 years post-surgery. Interestingly, this was not dissimilar to the mortality rate of patients with PJI treated with two-stage revision (35%) (12).

Health-care costs associated with DAIR

PJI is associated with a significant additional cost related to the delivery of care. Data from the USA suggest that the overall cost to the American health care system to treat PJI was \$566 million in 2009 alone, a number that is

Table 2 McPherson and colleagues staging system for PJI

Category	Grading	Considerations
Infection type	I	Early post-operative infection
	II	Acute haematogenous infection
	III	Late chronic infection
Systemic host	A	No compromise
	B	Compromised (≤2 factors)
	C	Significant compromise (>2 factors) or one of the following Absolute neutrophil count <1,000/mm ³ IV drug use Dysplasia or neoplasm or immune system
Local factors	1	No compromise
	2	1–2 compromising factors
	3	> 2 compromising factors

Systemic factor: age >80 years, alcoholism, nicotine use, chronic indwelling catheter, malnutrition, diabetes, liver, renal or pulmonary insufficiency; Local factors: acute infection present, multiple incisions, soft tissue loss, subcutaneous abscess, cutaneous fistula, prior articular trauma or fracture. PJI, periprosthetic joint infection.

projected to reach \$1.62 billion in 2020 (30). In Europe, the mean cost of a total joint arthroplasty is €7,200 (31). The excess cost is €12,800 for a DAIR and €44,600 for a two-stage revision. Looking at data from the USA (30), a DAIR procedure seems cost efficient as well as having the advantages of better functional outcome and improved quality of life compared to a two-stage revision (12,31).

Two studies have evaluated the health care cost differences between two stage, one stage and DAIR surgical options (32,33). The authors have noted that even though a DAIR approach may, in many cases, require a second surgical procedure, it is far more cost efficient, with less than half the cost of a 2-stage revision.

Factors associated with outcome

Patient-related factors

A number of patient-related factors have been associated with success following PJI. Thus, a host classification system is of significant value in the treatment of PJI. The McPherson Classification system is most commonly used (34) (Table 2). A number of studies have highlighted patient-specific factors that are associated with outcome post-DAIR (Table 1).

Because the implants are retained, the success of a DAIR

is probably dependent on the patient's immune system (15). Compromised host immunity, secondary to conditions such as diabetes, rheumatoid arthritis (RA) or other inflammatory disease has also been reported to lead to inferior outcomes with DAIR. The risk was greatest for late acute PJIs; failure rate was 74% in patients with RA compared to 43% in patients without RA.

McPherson host grade B and C are also associated with increased failure rates following DAIR compared to healthy individuals (35). An ASA grade of 3 or 4 has also been associated with a 7-fold increased in failure rate following DAIR in hip PJI (36). Similarly, obesity (BMI >30) is associated with increased failure rate following DAIR (15). Nicotine has also been associated with up to a 12-fold risk of recurrent PJI (13).

In more recent cohort studies of late acute PJIs, age over 80 has been independently associated with worse outcome. Male sex, chronic renal failure and liver cirrhosis were independent predictors of DAIR failure (37). However, it is important to consider that such factors are associated with inferior chances of successful outcome regardless of treatment modality offered (38-40).

Another major patient related factor is the quality of the soft tissue prior to surgery. Revision surgery may be associated with reduced bone-stock, compromised soft

Table 3 KLIC-score. Preoperative risk score developed to predict failure following DAIR for early acute PJIs

KLIC-score	Parameter	Individual parameter score	Total score	Failure rate (%)
K	Chronic renal failure (kidney)	2	≤2	4–5
L	Liver cirrhosis	1.5	2–3.5	19
I	Index surgery: indication prosthesis: fracture OR revision prosthesis	1.5	4–5	55
C	Cemented prosthesis	2	5.5–7	71
	CRP >115 mg/L	2.5	≥7	100

DAIR, antibiotic-treatment and implant-retention; PJI, periprosthetic joint infection.

Table 4 CRIME80 score. Preoperative risk score developed to predict failure following DAIR for acute hematogenous PJIs

CRIME80 score	Parameter	Point(s) allocated per parameter	Total score	Failure rate (%)
C	COPD	2	–1	22
	CRP >150 mg/L	1		
R	Rheumatoid arthritis	3	0	28
I	Indication prosthesis: fracture	3	1–2	40
M	Male	1	3–4	64
E	Exchange of mobile components	–1	≥5	79
80	Age 80 years	2		

DAIR, antibiotic-treatment and implant-retention; PJI, periprosthetic joint infection.

tissue envelope and greater amount of foreign material which likely contribute to the higher failure rate seen in the setting of revision THA (11,13,41). Lastly, the presence of a sinus tract is indicative of chronic PJI and a risk factor for failure (42–44).

Two scores have been used as prognostic indicators for success following DAIR; the KLIC (*Table 3*) and the CRIME80 (*Table 4*). However, these scores have not to date been validated by other authors.

PJI-related factors

Chronicity of symptoms

DAIR is an urgent; not an emergent procedure. Data have shown that interval between onset of symptoms and operation is an important factor influencing success. Exact cut-off intervals beyond which DAIR should not be attempted has not been determined. Nevertheless, symptoms less than one week were associated with higher chances of success (72.0% versus 51.8%, $P < 0.0001$).

Interval since surgery

Timing is of the essence in treating PJI. Multiple studies have found that DAIR within 6 weeks of index surgery is associated with improved chances of PJI eradication (7). The shorter the interval the better the success, especially if performed within 15 days of implantation (23). In various studies, chronic or late presenting infections appear to do poorly with DAIR and are better treated by revision surgery. However, some studies show an eradication of infection with one or two DAIR up to 85% if the implants are well fixed and the bone-cement interface intact (7,12), even in chronic infection.

The 2018 International Consensus Meeting says that there are no absolute contraindications to perform a DAIR procedure, but a DAIR should be discouraged when the chance of failure without removing the implants is very high (37). It is important to differentiate between chronic infection and acute late haematogenous spread. A careful history, including the index procedure post-operative course (wound healing, prolonged erythema, stiffness) and recent

illness (e.g., urinary tract or respiratory infections) should be taken to help establish chronicity.

Causative organism

The causative organism is an important factor contributing to the success or failure of DAIR. *Staphylococcus aureus* has been associated with higher rates of DAIR failure, with even worse results with methicillin resistant strain (MRSA) (11,13,14,36,42,45-49). In such cases success rate as low as 30% have been reported (36), however the results of MRSA being associated with higher failure rate is not universal (43). A study of a 386 early acute PJIs showed that the percentage of failure was 17% higher when *S. aureus* compared to other micro-organisms was the infective organism (50).

The presence of enterococcus has also been associated with high DAIR failure rate (53%) (18). We have previously noted that infection with *Streptococcus* species was associated with better outcome compared to other organisms (7).

Implant-related factors

DAIR procedures undertaken on primary arthroplasties performed for the treatment of hip fractures have been shown to have a significantly higher rate of failure (20–30% higher), compared to cases that were done for the treatment of primary osteoarthritis (18,50,51). There is little doubt that the inferior physiological reserve present in the elderly having received a hemiarthroplasty is contributing to the reduced chances of success. However, it is unknown whether the infective organism has also infected and resides in the acetabular surface (cartilage), thus reducing the chances of success without effective debridement and conversion to a total hip arthroplasty; further study is needed to evaluate this.

As aforementioned, revision cases have also been shown to be associated with inferior chances of success compared to primary cases (7).

There are little data regarding type of fixation and chances of success following DAIR. The presence of a cemented prosthesis was associated with inferior chances of success (OR: 8.7) in one study; however, the results of that study remain to be validated by others to date (18).

It is a matter of debate whether in cases with cemented femoral components of collarless, polished, tapered designs with macroscopically sound interfaces, the stem should be removed, and a new stem cemented in place. Although, such procedures would be associated with minimum morbidity, it would be considered as a revision arthroplasty

in registry data. Yet, such practice would undoubtedly reduce the biofilm presence and likely improve chances of success.

Surgical-related factors

Arthroscopic treatment

Although data on the use of arthroscopic treatment in PJI primarily stems from the knee literature, there is no doubt that arthroscopic debridement should not be the treatment of choice. This was also recommended by a strong majority in the recent International Consensus Meeting (37).

Exchange of modular parts

Exchange of modular parts is strongly advised as previously highlighted in the systematic review and our data (7,21). Exchanging the modular parts was associated with better chances of success (risk ratio: 3.7) and an improved 10-year implant survival (86% *vs.* 68%).

Drain

Using a drain to decrease dead space and prevent fluid accumulation is also generally well accepted. Drains are usually removed when there is minimal drainage (less than 50 cc/24 h), most often 48–72 h postoperatively (11,52).

Number of liters in wash and type of wash

No studies have reported on the optimum volume or type of fluid to be used. However, most would agree that 6–9 L of irrigation solution should be used. The solution should be either saline or a dilute anti-septic solution, mixed with saline (24).

Local antibiotic delivery

In order to improve/increase the level of antibiotic in the hip, local administration has been considered. Most of literature is focused on the use of catheters and pumps in the knee. However, the results have not shown a significant improvement in success rates (53-56).

There has been recent interest in the use of calcium sulphate beads as carriers for the delivery of local antibiotics. However, their efficacy has not been shown in high level evidence studies. Furthermore, certain complications have been associated with the self-degradation of the beads (i.e., transient hypercalcaemia and heterotopic ossification), which may compromise outcome. Current evidence does not support their routine use (57).

Antibiotic-related factors

Type of antibiotic regimen

Type of antibiotic used should be of course guided by the infection disease specialist taking into account host- and infective-organism characteristics. The use of Rifampicin has improved chances of success with sensitive bacterial species (58,59). Data of prospective cohort studies has shown that the use of fluoroquinolones in PJI's with sensitive gram negative species is protective and associated with lower failure rate (7.1%) compared to other antibiotic regimens (37.5%) (P=0.04) (60).

Duration of treatment

A recent study found that DAIR in hip PJI had an overall success rate of 83% with additional chronic antibiotic suppression for the implant and/or the patient's life (35). Such an approach should be used with caution as chronic antibiotic suppression therapy may lead to other problems, such as antibiotic resistance. Thus, it should be restricted to a minimum number of patients, i.e., those too frail to go through further surgery if deemed necessary.

Most studies use between 3 and 6 months of antibiotic therapy duration. Byren *et al.* showed that prolonging antibiotic treatment only postpones rather than prevents failure (11).

Closing statement

DAIR is a valuable option in the treatment of hip PJI. Singly, and when necessary repeated, DAIR can achieve infection eradication in the majority of cases of patients in the hands of experienced surgeons in specialised centres with a multi-disciplinary team approach. DAIR should always be considered as a treatment option despite interval from index procedure if the bone-implant interfaces are stable. Exchange of modular components and thorough debridement are paramount (12). Prospective studies are sparse and necessary to test the efficacy of the DAIR in an MDT setting.

Acknowledgments

The authors would like to acknowledge Ms C. Kreviazuk's work and efforts in the preparation and submission of this manuscript.

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the Guest Editors (Nemandra A. Sandiford, Massimo Francescini and Daniel Kendoff) for the series "Prosthetic Joint Infection" published in *Annals of Joint*. The article has undergone external peer review.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <http://dx.doi.org/10.21037/aoj-20-87>). The series "Prosthetic Joint Infection" was commissioned by the editorial office without any funding or sponsorship. GG serves as an unpaid editorial board member of *Annals of Joint* from May 2019 to April 2021. BK reports personal fees from DePuy, personal fees from Zimmer, personal fees from Corin, outside the submitted work. AT reports personal fees from DePuy, personal fees from Corin, outside the submitted work. GG reports grants from Canadian Institutes of Health Research, outside the submitted work. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This study was conducted under a Continuous Quality Improvement Initiative at The Ottawa Hospital and institutional ethics committee approval was not required.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

- Engesæter LB, Dale H, Schrama JC, et al. Surgical procedures in the treatment of 784 infected THAs reported to the Norwegian Arthroplasty Register: Best survival with 2-stage exchange revision, but also good results with debridement and retention of the fixed

- implant. *Acta Orthop* 2011;82:530-7.
2. Berend KR, Lombardi AV, Morris MJ, et al. Two-stage treatment of hip periprosthetic joint infection is associated with a high rate of infection control but high mortality. *Clin Orthop Relat Res* 2013;471:510-8.
 3. Oussedik SI, Dodd M, Haddad F. Outcomes of revision total hip replacement for infection after grading according to a standard protocol. *J Bone Joint Surg Br* 2010;92:1222-6.
 4. Vanhegan IS, Malik A, Jayakumar P, et al. A financial analysis of revision hip arthroplasty: the economic burden in relation to the national tariff. *J Bone Joint Surg Br* 2012;94:619-23.
 5. Knebel C, Menzemer J, Pohlig F, et al. Peri-Prosthetic Joint Infection of the Knee Causes High Levels of Psychosocial Distress: A Prospective Cohort Study. *Surg Infect (Larchmt)* 2020;21:877-83.
 6. Coventry MB. Treatment of infections occurring in total hip surgery. *Orthop Clin North Am* 1975;6:991-1003.
 7. Grammatopoulos G, Kendrick B, McNally M, et al. Outcome following debridement, antibiotics, and implant retention in hip periprosthetic joint infection—an 18-year experience. *J Arthroplasty* 2017;32:2248-55.
 8. Palmer AJR, Lloyd TD, Gibbs VN, et al. The role of intra-operative cell salvage in patient blood management for revision hip arthroplasty: a prospective cohort study. *Anaesthesia* 2020;75:479-86.
 9. Parvizi J, Zmistowski B, Berbari EF, et al. New definition for periprosthetic joint infection: from the Workgroup of the Musculoskeletal Infection Society. *Clin Orthop Relat Res* 2011;469:2992.
 10. Parvizi J, Tan TL, Goswami K, et al. The 2018 definition of periprosthetic hip and knee infection: an evidence-based and validated criteria. *J Arthroplasty* 2018;33:1309-14. e2.
 11. Byren I, Bejon P, Atkins B, et al. One hundred and twelve infected arthroplasties treated with 'DAIR' (debridement, antibiotics and implant retention): antibiotic duration and outcome. *J Antimicrob Chemother* 2009;63:1264-71.
 12. Grammatopoulos G, Bolduc M, Atkins B, et al. Functional outcome of debridement, antibiotics and implant retention in periprosthetic joint infection involving the hip: a case-control study. *Bone Joint J* 2017;99-B:614-22.
 13. Everhart JS, Altneun E, Calhoun JH. Medical comorbidities are independent preoperative risk factors for surgical infection after total joint arthroplasty. *Clin Orthop Relat Res* 2013;471:3112-9.
 14. Buller LT, Sabry FY, Easton RW, et al. The preoperative prediction of success following irrigation and debridement with polyethylene exchange for hip and knee prosthetic joint infections. *J Arthroplasty* 2012;27:857-64.e1.
 15. Triantafyllopoulos GK, Poultsides LA, Sakellariou VI, et al. Irrigation and debridement for periprosthetic infections of the hip and factors determining outcome. *Int Orthop* 2015;39:1203-9.
 16. Kuiper JW, Vos SJ, Saouti R, et al. Prosthetic joint-associated infections treated with DAIR (debridement, antibiotics, irrigation, and retention) Analysis of risk factors and local antibiotic carriers in 91 patients. *Acta Orthop* 2013;84:380-6.
 17. Sukeik M, Patel S, Haddad FS. Aggressive early debridement for treatment of acutely infected cemented total hip arthroplasty. *Clin Orthop Relat Res* 2012;470:3164-70.
 18. Tornero E, Morata L, Martínez-Pastor J, et al. KLIC-score for predicting early failure in prosthetic joint infections treated with debridement, implant retention and antibiotics. *Clin Microbiol Infect* 2015;21:786.e9-786.e17.
 19. Westberg M, Grøgaard B, Snorrason F. Early prosthetic joint infections treated with debridement and implant retention: 38 primary hip arthroplasties prospectively recorded and followed for median 4 years. *Acta Orthop* 2012;83:227-32.
 20. Kilgus DJ, Howe DJ, Strang A. Results of periprosthetic hip and knee infections caused by resistant bacteria. *Clin Orthop Relat Res* 2002;404:116-24.
 21. Tsang SJ, Ting J, Simpson A, et al. Outcomes following debridement, antibiotics and implant retention in the management of periprosthetic infections of the hip: a review of cohort studies. *Bone Joint J* 2017;99-B:1458-66.
 22. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. *N Engl J Med* 2004;351:1645-54.
 23. Tornero E, Martínez-Pastor JC, Bori G, et al. Risk factors for failure in early prosthetic joint infection treated with debridement. Influence of etiology and antibiotic treatment. *J Appl Biomater Funct Mater* 2014;12:129-34.
 24. Novembri Utomo D, Budhiparama N, Battenberg A, et al. Question 8: Can debridement, antibiotics and implant retention (DAIR) be utilized in the treatment of acute periprosthetic joint infection (PJI) with a megaprosthesis? International Consensus Meeting (ICM) on Musculoskeletal Infection; Philadelphia, USA. 2018.
 25. Alvand A, Grammatopoulos G, de Vos F, et al. Clinical Outcome of Massive Endoprostheses Used for Managing Periprosthetic Joint Infections of the Hip and Knee. *J Arthroplasty* 2018;33:829-34.
 26. Aboltins C, Dowsey M, Peel T, et al. Early prosthetic

- hip joint infection treated with debridement, prosthesis retention and biofilm-active antibiotics: functional outcomes, quality of life and complications. *Intern Med J* 2013;43:810-5.
27. Cobo J, San Miguel LG, Euba G, et al. Early prosthetic joint infection: outcomes with debridement and implant retention followed by antibiotic therapy. *Clin Microbiol Infect* 2011;17:1632-7.
 28. Dzaja I, Howard J, Somerville L, et al. Functional outcomes of acutely infected knee arthroplasty: a comparison of different surgical treatment options. *Can J Surg* 2015;58:402-7.
 29. Gundtoft PH, Pedersen AB, Varnum C, et al. Increased mortality after prosthetic joint infection in primary THA. *Clin Orthop Relat Res* 2017;475:2623-31.
 30. Tande AJ, Patel R. Prosthetic joint infection. *Clin Microbiol Rev* 2014;27:302-45.
 31. Puhto T, Puhto AP, Vielma M, et al. Infection triples the cost of a primary joint arthroplasty. *Infect Dis (Lond)* 2019;51:348-55.
 32. Merollini KM, Zheng H, Graves N. Most relevant strategies for preventing surgical site infection after total hip arthroplasty: guideline recommendations and expert opinion. *Am J Infect Control* 2013;41:221-6.
 33. Haddad F, Ngu A, Negus J. Prosthetic joint infections and cost analysis? A Modern Approach to Biofilm-Related Orthopaedic Implant Infections. Springer; 2017:93-100.
 34. McPherson EJ, Woodson C, Holtom P, et al. Periprosthetic total hip infection: outcomes using a staging system. *Clin Orthop Relat Res* 2002;8-15.
 35. Bryan AJ, Abdel MP, Sanders TL, et al. Irrigation and debridement with component retention for acute infection after hip arthroplasty: improved results with contemporary management. *J Bone Joint Surg Am* 2017;99:2011-8.
 36. Azzam KA, Seeley M, Ghanem E, et al. Irrigation and debridement in the management of prosthetic joint infection: traditional indications revisited. *J Arthroplasty* 2010;25:1022-7.
 37. Parvizi J, Gehrke T. Proceedings of the Second International Consensus Meeting on Musculoskeletal Infection. 2018.
 38. Xu C, Kuo FC, Kheir M, et al. Outcomes and predictors of treatment failure following two-stage total joint arthroplasty with articulating spacers for evolutive septic arthritis. *BMC Musculoskelet Disord* 2019;20:272.
 39. Kandel CE, Jenkinson R, Daneman N, et al. Predictors of Treatment Failure for Hip and Knee Prosthetic Joint Infections in the Setting of 1- and 2-Stage Exchange Arthroplasty: A Multicenter Retrospective Cohort. *Open Forum Infect Dis* 2019;6:ofz452.
 40. Cancienne JM, Werner BC, Bolarinwa SA, et al. Removal of an Infected Total Hip Arthroplasty: Risk Factors for Repeat Debridement, Long-term Spacer Retention, and Mortality. *J Arthroplasty* 2017;32:2519-22.
 41. Siqueira MB, Saleh A, Klika AK, et al. Chronic suppression of periprosthetic joint infections with oral antibiotics increases infection-free survivorship. *J Bone Joint Surg Am* 2015;97:1220-32.
 42. Qasim SN, Swann A, Ashford R. The DAIR (debridement, antibiotics and implant retention) procedure for infected total knee replacement - a literature review. *SICOT J* 2017;3:2.
 43. Lora-Tamayo J, Murillo O, Iribarren JA, et al. A large multicenter study of methicillin-susceptible and methicillin-resistant *Staphylococcus aureus* prosthetic joint infections managed with implant retention. *Clin Infect Dis* 2013;56:182-94.
 44. Marculescu CE, Berbari E, Hanssen A, et al. Outcome of prosthetic joint infections treated with debridement and retention of components. *Clin Infect Dis* 2006;42:471-8.
 45. Gardner J, Gioe TJ, Tatman P. Can this prosthesis be saved?: implant salvage attempts in infected primary TKA. *Clin Orthop Relat Res* 2011;469:970-6.
 46. Koyonos L, Zmistowski B, Della Valle CJ, et al. Infection control rate of irrigation and debridement for periprosthetic joint infection. *Clin Orthop Relat Res* 2011;469:3043.
 47. Barberán J, Aguilar L, Carroquino G, et al. Conservative treatment of staphylococcal prosthetic joint infections in elderly patients. *Am J Med* 2006;119:993.e7-10.
 48. Chaussade H, Uçkay I, Vuagnat A, et al. Antibiotic therapy duration for prosthetic joint infections treated by debridement and implant retention (DAIR): similar long-term remission for 6 weeks as compared to 12 weeks. *Int J Infect Dis* 2017;63:37-42.
 49. Zürcher-Pfund L, Uçkay I, Legout L, et al. Pathogen-driven decision for implant retention in the management of infected total knee prostheses. *Int Orthop* 2013;37:1471-5.
 50. Löwik CA, Jutte PC, Tornero E, et al. Predicting failure in early acute prosthetic joint infection treated with debridement, antibiotics, and implant retention: external validation of the KLIC score. *J Arthroplasty* 2018;33:2582-7.
 51. Bergkvist M, Mukka SS, Johansson L, et al. Debridement, antibiotics and implant retention in early periprosthetic joint infection. *Hip Int* 2016;26:138-43.

52. Sendi P, Löttscher P, Kessler B, et al. Debridement and implant retention in the management of hip periprosthetic joint infection: outcomes following guided and rapid treatment at a single centre. *Bone Joint J* 2017;99-B:330-6.
53. Whiteside LA, Peppers M, Nayfeh TA, et al. Methicillin-resistant *Staphylococcus aureus* in TKA treated with revision and direct intraarticular antibiotic infusion. *Clin Orthop Relat Res* 2011;469:26-33.
54. Whiteside LA, Nayfeh TA, LaZear R, et al. Reinfected revised TKA resolves with an aggressive protocol and antibiotic infusion. *Clin Orthop Relat Res* 2012;470:236-43.
55. Roy ME, Peppers MP, Whiteside LA, et al. Vancomycin concentration in synovial fluid: direct injection into the knee vs. intravenous infusion. *J Arthroplasty* 2014;29:564-8.
56. Antony SJ, Westbrook RS, Jackson JS, et al. Efficacy of single-stage revision with aggressive debridement using intra-articular antibiotics in the treatment of infected joint prosthesis. *Infect Dis (Auckl)* 2015;8:17-23.
57. Abosala A, Ali M. The Use of Calcium Sulphate beads in Periprosthetic Joint Infection, a systematic review. *J Bone Jt Infect* 2020;5:43.
58. Zimmerli W, Widmer AF, Blatter M, et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. *JAMA* 1998;279:1537-41.
59. Holmberg A, Thórhallsdóttir VG, Robertsson O, et al. 75% success rate after open debridement, exchange of tibial insert, and antibiotics in knee prosthetic joint infections: Report on 145 cases from the Swedish Knee Arthroplasty Register. *Acta Orthop* 2015;86:457-62.
60. Tornero E, Morata L, Martínez-Pastor JC, et al. Importance of selection and duration of antibiotic regimen in prosthetic joint infections treated with debridement and implant retention. *J Antimicrob Chemother* 2016;71:1395-401.

doi: 10.21037/aoj-20-87

Cite this article as: Bolduc MÈ, Fischman D, Kendrick B, Taylor A, Grammatopoulos G. Contemporary outcomes of debridement, antibiotics and implant retention (DAIR) in hip arthroplasty. *Ann Joint* 2021;6:42.